“Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience”, Arch Ital Urol Androl, vol. 89, no. 4, pp. 272–276, Dec. 2017, doi: 10.4081/aiua.2017.4.272.